Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Update

Plus Therapeutics, Inc. (NASDAQ:PSTV) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 23,932,707 shares, an increase of 19.0% from the March 15th total of 20,108,546 shares. Based on an average trading volume of 5,057,822 shares, the short-interest ratio is presently 4.7 days. Currently, 351.5% of the shares of the company are short sold.

Analyst Ratings Changes

PSTV has been the topic of a number of recent analyst reports. Ascendiant Capital Markets decreased their target price on shares of Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective (down from $50.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $58.00.

Plus Therapeutics Price Performance

Plus Therapeutics stock opened at $6.39 on Friday. The firm’s 50 day moving average price is $6.14 and its 200-day moving average price is $10.78. Plus Therapeutics has a 1 year low of $2.90 and a 1 year high of $30.50. The stock has a market cap of $43.84 million, a P/E ratio of -0.21 and a beta of 1.03.

Plus Therapeutics (NASDAQ:PSTV) last posted its earnings results on Thursday, March 12th. The company reported $6.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $6.28. The business had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $1.23 million. As a group, equities analysts expect that Plus Therapeutics will post -2.3 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PSTV. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics in the second quarter valued at $41,000. Susquehanna International Group LLP purchased a new position in shares of Plus Therapeutics in the third quarter valued at $46,000. Scientech Research LLC purchased a new position in shares of Plus Therapeutics in the third quarter valued at $100,000. XTX Topco Ltd purchased a new position in shares of Plus Therapeutics in the fourth quarter valued at $127,000. Finally, State Street Corp grew its holdings in shares of Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares in the last quarter. 3.28% of the stock is owned by hedge funds and other institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.